M Jongen-Lavrencic
Overview
Explore the profile of M Jongen-Lavrencic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
458
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van de Loosdrecht A, Cremers E, Alhan C, Duetz C, In t Hout F, Visser-Wisselaar H, et al.
Leukemia
. 2024 Jan;
38(4):840-850.
PMID: 38297135
A randomized phase-II study was performed in low/int-1 risk MDS (IPSS) to study efficacy and safety of lenalidomide without (arm A) or with (arm B) ESA/G-CSF. In arm B, patients...
2.
Janssen J, Lowenberg B, Manz M, Biemond B, Westerweel P, Klein S, et al.
Leukemia
. 2022 Jul;
36(9):2189-2195.
PMID: 35869267
Treatment results of AML in elderly patients are unsatisfactory. In an open label randomized phase II study, we investigated whether addition of the XPO1 inhibitor selinexor to intensive chemotherapy would...
3.
Ossenkoppele G, Breems D, Stuessi G, van Norden Y, Bargetzi M, Biemond B, et al.
Leukemia
. 2020 Aug;
34(10):2820.
PMID: 32733013
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
4.
Ossenkoppele G, Breems D, Stuessi G, van Norden Y, Bargetzi M, Biemond B, et al.
Leukemia
. 2020 Feb;
34(7):1751-1759.
PMID: 32020044
More effective treatment modalities are urgently needed in patients with acute myeloid leukemia (AML) of older age. We hypothesized that adding lenalidomide to intensive standard chemotherapy might improve their outcome....
5.
Dinmohamed A, van Norden Y, van de Loosdrecht A, Jongen-Lavrencic M
Leukemia
. 2016 May;
30(8):1795-6.
PMID: 27198054
No abstract available.
6.
Dinmohamed A, Brink M, Visser O, Jongen-Lavrencic M
Leukemia
. 2016 Apr;
30(6):1449-51.
PMID: 27055870
No abstract available.
7.
Nowek K, Sun S, Dijkstra M, Bullinger L, Dohner H, Erkeland S, et al.
Leukemia
. 2015 Oct;
30(2):303-9.
PMID: 26464168
In double-stranded miRNA/miRNA* duplexes, one of the strands represents an active miRNA, whereas another, known as a passenger strand (miRNA*), is typically degraded. MiR-9* is not detectable in normal myeloid...
8.
Dinmohamed A, van Norden Y, Visser O, Posthuma E, Huijgens P, Sonneveld P, et al.
Leukemia
. 2015 Sep;
29(12):2449-51.
PMID: 26369829
No abstract available.
9.
Dinmohamed A, Szabo A, Van der Mark M, Visser O, Sonneveld P, Cornelissen J, et al.
Leukemia
. 2015 Aug;
30(2):310-7.
PMID: 26286115
This nationwide population-based study assessed trends in treatment, trial participation and survival among 1833 adult patients diagnosed with acute lymphoblastic leukemia (ALL) in the Netherlands between 1989 and 2012 reported...
10.
Dinmohamed A, Visser O, van Norden Y, Blijlevens N, Cornelissen J, Huls G, et al.
Leukemia
. 2015 Jul;
30(1):24-31.
PMID: 26183645
Large, comprehensive population-based studies in acute myeloid leukemia (AML) are scarce. We conducted a nationwide population-based study on treatment, trial participation and survival among all adult patients diagnosed with AML...